Drugs / Fluorizoparib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07371910 | Jun 2024 → Mar 2031 expected | Her2-receptor negative breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluorizoparib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07371910 ↗ |
| Action | Inhibit | “This oral PARP inhibitor is administered as part of the maintenance phase.” NCT07371910 ↗ |
| Modality | Small molecule | “This oral PARP inhibitor is administered as part of the maintenance phase.” NCT07371910 ↗ |
| Route | Oral | “This oral PARP inhibitor is administered as part of the maintenance phase.” NCT07371910 ↗ |